Icosavax Statistics
Total Valuation
Icosavax has a market cap or net worth of $766.88 million. The enterprise value is $545.75 million.
Market Cap | 766.88M |
Enterprise Value | 545.75M |
Important Dates
The last earnings date was Thursday, March 28, 2024, after market close.
Earnings Date | Mar 28, 2024 |
Ex-Dividend Date | n/a |
Share Statistics
Icosavax has 50.09 million shares outstanding. The number of shares has increased by 25.87% in one year.
Current Share Class | n/a |
Shares Outstanding | 50.09M |
Shares Change (YoY) | +25.87% |
Shares Change (QoQ) | +11.75% |
Owned by Insiders (%) | 3.47% |
Owned by Institutions (%) | 87.63% |
Float | 29.30M |
Valuation Ratios
PE Ratio | n/a |
Forward PE | n/a |
PS Ratio | n/a |
Forward PS | n/a |
PB Ratio | 3.30 |
P/TBV Ratio | n/a |
P/FCF Ratio | n/a |
P/OCF Ratio | n/a |
PEG Ratio | n/a |
Enterprise Valuation
EV / Earnings | n/a |
EV / Sales | n/a |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 18.06, with a Debt / Equity ratio of 0.03.
Current Ratio | 18.06 |
Quick Ratio | n/a |
Debt / Equity | 0.03 |
Debt / EBITDA | n/a |
Debt / FCF | n/a |
Interest Coverage | 64.71 |
Financial Efficiency
Return on equity (ROE) is -43.10% and return on invested capital (ROIC) is -44.04%.
Return on Equity (ROE) | -43.10% |
Return on Assets (ROA) | -39.50% |
Return on Capital (ROIC) | -44.04% |
Revenue Per Employee | n/a |
Profits Per Employee | -$1.61M |
Employee Count | 60 |
Asset Turnover | n/a |
Inventory Turnover | n/a |
Taxes
Income Tax | n/a |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +68.80% in the last 52 weeks. The beta is 1.28, so Icosavax's price volatility has been higher than the market average.
Beta (5Y) | 1.28 |
52-Week Price Change | +68.80% |
50-Day Moving Average | 15.18 |
200-Day Moving Average | 10.11 |
Relative Strength Index (RSI) | 55.41 |
Average Volume (20 Days) | 1,438,820 |
Short Selling Information
The latest short interest is 321,311, so 0.64% of the outstanding shares have been sold short.
Short Interest | 321,311 |
Short Previous Month | 499,714 |
Short % of Shares Out | 0.64% |
Short % of Float | 1.10% |
Short Ratio (days to cover) | 0.34 |
Income Statement
Revenue | n/a |
Gross Profit | n/a |
Operating Income | -105.88M |
Pretax Income | -96.71M |
Net Income | -96.71M |
EBITDA | -95.28M |
EBIT | -98.23M |
Earnings Per Share (EPS) | -$2.22 |
Balance Sheet
The company has $229.21 million in cash and $8.07 million in debt, giving a net cash position of $221.14 million or $4.41 per share.
Cash & Cash Equivalents | 229.21M |
Total Debt | 8.07M |
Net Cash | 221.14M |
Net Cash Per Share | $4.41 |
Equity (Book Value) | 232.38M |
Book Value Per Share | 4.64 |
Working Capital | 222.28M |
Cash Flow
In the last 12 months, operating cash flow was -$68.85 million and capital expenditures -$4.83 million, giving a free cash flow of -$73.68 million.
Operating Cash Flow | -68.85M |
Capital Expenditures | -4.83M |
Free Cash Flow | -73.68M |
FCF Per Share | -$1.47 |
Margins
Gross Margin | n/a |
Operating Margin | n/a |
Pretax Margin | n/a |
Profit Margin | n/a |
EBITDA Margin | n/a |
EBIT Margin | n/a |
FCF Margin | n/a |
Dividends & Yields
Icosavax does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | n/a |
Buyback Yield | -25.87% |
Shareholder Yield | -25.87% |
Earnings Yield | -12.61% |
FCF Yield | -9.61% |
Analyst Forecast
The average price target for Icosavax is $25.00, which is 63.29% higher than the current price. The consensus rating is "Buy".
Price Target | $25.00 |
Price Target Difference | 63.29% |
Analyst Consensus | Buy |
Analyst Count | 2 |
Revenue Growth Forecast (5Y) | 182.69% |
EPS Growth Forecast (5Y) | n/a |
Stock Splits
This stock does not have any record of stock splits.
Last Split Date | n/a |
Split Type | n/a |
Split Ratio | n/a |
Scores
Altman Z-Score | n/a |
Piotroski F-Score | 2 |